ReviewRespiratory medicine2026
Predictors of respiratory decline in neuromuscular disorders.
Review in Respiratory medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Neuromuscular diseases (NMDs) constitute a heterogeneous group of genetic and acquired disorders that lead to progressive muscle weakness. When the respiratory muscles are involved, impaired ventilation and ineffective airway clearance become a major source of morbidity and mortality. Respiratory insufficiency is one of the major contributors to mortality in NMDs, with considerable variation in onset and rate of progression across different diseases. Patients with NMD have progressive weakness of the diaphragm and accessory respiratory muscles. This weakness leads to reduced chest wall compliance and restrictive lung disease. In some NMDs, bulbar dysfunction results in impaired airway clearance and aspiration pneumonia. Despite advances in care, predicting the onset of respiratory decline in NMDs remains a major clinical challenge. This narrative review aims to synthesize the current evidence on predictors of respiratory decline in NMDs. We comprehensively evaluate a broad spectrum of clinical, physiological, cellular, imaging, genetic, and digital markers that have emerged as predictors for respiratory decline in NMDs. These include age-related trends, pulmonary function tests, strength assessments, advanced imaging modalities, blood and serum biomarkers, genetic variants, scoring systems, and emerging smartphone based tools. By highlighting these factors, we underscore their potential to improve the early detection of respiratory impairment and guide timely interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.